27 results
DEF 14A
MREO
Mereo Biopharma Group Plc
24 Apr 24
Definitive proxy
7:30am
. Pakianathan is considered an “audit committee financial expert” as defined by applicable SEC rules and has the requisite financial sophistication as defined … standards provided by Nasdaq and the SEC, and the Board has determined that Dr. Pakianathan is an “Audit and Risk Committee financial expert
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
an “audit committee financial expert” as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable
10-K
2023 FY
EX-10.30
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
; and
WHEREAS, ReproNovo has access to market information, experience in business practices and expert knowledge in relation to the registration
6-K
MREO
Mereo Biopharma Group Plc
10 Nov 22
Current report (foreign)
4:06pm
.
The Board has determined that Dr. Pakianathan qualifies to serve as an “audit committee financial expert” as defined under applicable rules
6-K
MREO
Mereo Biopharma Group Plc
26 May 22
Current report (foreign)
4:11pm
expert” as defined under applicable rules of the Securities and Exchange Commission, and has the requisite financial sophistication as defined under
F-3
EX-4.4
vsefe
5 Aug 21
Shelf registration (foreign)
4:33pm
F-3
EX-4.3
yfw248eck i40zwrz
5 Aug 21
Shelf registration (foreign)
4:33pm
6-K
zqja6p2r3g1p
1 Oct 20
Current report (foreign)
4:30pm
6-K
oegzv27n
3 Aug 20
Current report (foreign)
9:15am
F-1/A
dt67mgsngp7vw8fokn
12 Mar 20
Registration statement (foreign) (amended)
5:15pm
F-1/A
w92o cc4mcighk86otv
6 Mar 20
Registration statement (foreign) (amended)
5:32pm
6-K
ukndqrfm t3yk
16 Jul 19
Current report (foreign)
8:21am